Bausch Health Companies Inc. (TSX: BHC)
Canada
· Delayed Price · Currency is CAD
10.79
+0.02 (0.19%)
Jan 30, 2025, 4:00 PM EST
Bausch Health Companies Revenue
Bausch Health Companies had revenue of $2.51B USD in the quarter ending September 30, 2024, with 12.15% growth. This brings the company's revenue in the last twelve months to $9.47B, up 10.91% year-over-year. In the year 2023, Bausch Health Companies had annual revenue of $8.76B with 7.79% growth.
Revenue (ttm)
$9.47B
Revenue Growth
+10.91%
P/S Ratio
n/a
Revenue / Employee
$467.39K
Employees
20,270
Market Cap
3.97B CAD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8.76B | 633.00M | 7.79% |
Dec 31, 2022 | 8.12B | -310.00M | -3.68% |
Dec 31, 2021 | 8.43B | 407.00M | 5.07% |
Dec 31, 2020 | 8.03B | -574.00M | -6.67% |
Dec 31, 2019 | 8.60B | 221.00M | 2.64% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Green Thumb Industries | 1.51B |
WELL Health Technologies | 957.69M |
dentalcorp Holdings | 1.51B |
Curaleaf Holdings | 1.83B |
Trulieve Cannabis | 1.58B |
Sienna Senior Living | 867.55M |
Cronos Group | 150.26M |
Extendicare | 1.42B |
Bausch Health Companies News
- 7 days ago - Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025 - Accesswire
- 7 days ago - Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025 - Accesswire
- 8 days ago - Bausch Health Swaps Out Advisers After Years of Debt, Sale Talks - BNN Bloomberg
- 8 days ago - Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19 - Business Wire
- 13 days ago - Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program - Accesswire
- 14 days ago - FDA grants tentative approval for Amneal generic of Bausch Health's Xiafan - Seeking Alpha
- 16 days ago - Bausch and Lomb CEO: Right on track with our important initiatives - CNBC
- 17 days ago - George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia and Central America - GlobeNewsWire